The Controlled Particle Dispersion technology's ability to
saturate the nasal mucosa and deliver to the paranasal sinuses
can dramatically improve treatment of conditions such as
rhinitis, chronic rhinosinusitis, cold and influenza.
Intranasal corticosteroids (INSs) effectively reduce the nasal
inflammation that is a root cause of allergic rhinitis. By acting
early and throughout the allergy process, INSs block more allergy
mediators, treating the symptoms caused by nasal inflammation such
as nasal congestion, sneezing, and runny or itchy nose. This class
of medicine is considered first-line therapy when nasal congestion
is the primary symptom of the patient's rhinitis.